Polygenic Risk Score Predicts Prognosis in Nonobese Metabolic Dysfunction-Associated Steatotic Liver Disease but not in Obese Metabolic Dysfunction-Associated Steatotic Liver Disease in Japan: A Multicenter Cohort Study
Clinical Gastroenterology and Hepatology · 2026-05
DOI: 10.1016/j.cgh.2026.04.026 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-05. Verfasst von Takao Shirono und 12 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: Ministry of Education, Culture, Sports, Science and Technology.
Abstract (Originalsprache)
BACKGROUND & AIMS: Prognosis in nonobese vs obese metabolic dysfunction-associated steatotic liver disease remains uncertain, and genetic effects may differ by obesity. We examined whether a 2-variant polygenic risk score (PNPLA3 rs738409 and TM6SF2 rs58542926) predicts liver-related events and overall survival across obesity strata. METHODS: This multicenter Japan Genetic Study of Nonalcoholic Fatty Liver Disease Research (JAGUAR) cohort included 1304 Japanese patients with biopsy-proven metabolic dysfunction-associated steatotic liver disease. We examined the relationship between the 2-variant polygenic risk score and liver-related events or overall survival according to obesity status. External validation used an independent Korean, nonbiopsied cohort; validation focused on overall survival, including a clinically enriched subset with fatty liver and Fibrosis-4 index >1.3. RESULTS: Median follow-up was 8.1 years (range, 1.0-24.0). Overall, 103 liver-related events (7.9%) and 65 deaths (5.0%) occurred; 10-year liver-related event incidence was 10.1% and 10-year overall survival was 95.0%. Liver-related event risk did not differ by obesity (10.0% vs10.4%). Two-variant polygenic risk score independently predicted liver-related events in both strata (per 0.1-unit: obese hazard ratio, 1.207; nonobese hazard ratio, 1.454). For overall survival, the 2-variant polygenic risk score was significant only in nonobese patients (hazard ratio, 1.365), not in obese patients. Adding the 2-variant polygenic risk score improved discrimination in nonobese patients for both liver-related events and overall survival but not for overall survival in obese patients. In external validation, the 2-variant polygenic risk score was not significantly associated with overall survival, including in the enriched subset. CONCLUSIONS: In biopsy-proven metabolic dysfunction-associated steatotic liver disease, the 2-variant polygenic risk score improves liver-related event prediction regardless of obesity and shows the strongest association with overall survival among nonobese patients; these overall survival associations were not reproduced in a predominantly mild-spectrum, nonbiopsied cohort.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
- Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
- Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan. Electronic address: yuyaseko@koto.kpu-m.ac.jp.
- Department of Internal Medicine, Hanyang University College of Medicine, Seoul, South Korea.
- Department of Gastroenterology and Hepatology, Saiseikai Suita Hospital, Suita, Japan.
- Division of Metabolism and Endocrinology, Department of Hepatology, Faculty of Medicine, Saga University, Saga, Japan; Liver Center, Saga University Hospital, Saga, Japan.
Förderung
- Ministry of Education, Culture, Sports, Science and Technology
Zitieren
APA
Shirono, T., Iwaki, M., Seko, Y., Jun, D. W., Shima, T., Takahashi, H., Kawanaka, M., Tanaka, S., Yamaguchi, K., Yoneda, M., Nakajima, A., Itoh, Y., & Okanoue, T. (2026). Polygenic Risk Score Predicts Prognosis in Nonobese Metabolic Dysfunction-Associated Steatotic Liver Disease but not in Obese Metabolic Dysfunction-Associated Steatotic Liver Disease in Japan: A Multicenter Cohort Study. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2026.04.026
Vancouver
Shirono T, Iwaki M, Seko Y, Jun DW, Shima T, Takahashi H, et al. Polygenic Risk Score Predicts Prognosis in Nonobese Metabolic Dysfunction-Associated Steatotic Liver Disease but not in Obese Metabolic Dysfunction-Associated Steatotic Liver Disease in Japan: A Multicenter Cohort Study. Clinical Gastroenterology and Hepatology. 2026. doi:10.1016/j.cgh.2026.04.026
BibTeX
@article{Shirono2026,
author = {Shirono, Takao and Iwaki, Michihiro and Seko, Yuya and Jun, Dae Won and Shima, Toshihide and Takahashi, Hirokazu and Kawanaka, Miwa and Tanaka, Saiyu and Yamaguchi, Kanji and Yoneda, Masato and Nakajima, Atsushi and Itoh, Yoshito and Okanoue, Takeshi},
title = {Polygenic Risk Score Predicts Prognosis in Nonobese Metabolic Dysfunction-Associated Steatotic Liver Disease but not in Obese Metabolic Dysfunction-Associated Steatotic Liver Disease in Japan: A Multicenter Cohort Study},
journal = {Clinical Gastroenterology and Hepatology},
year = {2026},
doi = {10.1016/j.cgh.2026.04.026}
}
EUVIMED